NPS Pharma Poised for Significant Upside and 4 Stock Analyses Circulating Mid-Week

NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) price target has been increased by Jefferies following an FDA panel’s vote for recommending approval of the company’s Gattex drug. The firm believes that there is potential for significant share upside, and it keeps its Buy rating on the stock.

Google Inc. (NASDAQ:GOOG): Jefferies has stated that its channel checks suggest that Google Shopping has begun to experience strong adoption by retailers as it transitions to a fee-based program. The firm thinks that Google is in the ideal position for a solid second half of 2012, and it maintains its Buy rating and an $850 price target on the stock.

Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>

Forest Laboratories Inc. (NYSE:FRX) reported lower than expected Q2 revenue but higher than expected Q2 EPS, and it lowered its FY13 guidance. This has caused Cantor to think that the company will have multiple positive data catalysts next year, and the firm continues to be upbeat in regards to the company’s late stage pipeline. The firm keeps its Buy rating and a $47 target on the stock.

BroadSoft, Inc. (NASDAQ:BSFT): William Blair believes that Cisco’s (NASDAQ:CSCO) new Hosted Collaboration Solution will not have much of an impact on BroadSoft. The firm views Cisco’s announcements yesterday as being unable to change the competitive landscape, and it maintains its Outperform rating on the stock.

Life Time Fitness Inc. (NYSE:LTM) membership trends are expected by Cantor to see improvement with the decline of unemployment. The firm keeps its Outperform rating and a $60 price target on the stock.

Don’t Miss: Will New Free Trade Negotiations Spur Growth in the U.S. and Europe?